重组人血管内皮抑制素联合EP方案对小细胞肺癌细胞株NCI-H446的增殖抑制和促细胞凋亡作用

EP regimen combined with recombinant human vascular endostatin (Endostar) inhibits the proliferation of small-cell lung cancer cell Line NCI-H446 and promotes the apoptosis

目的:本研究旨在评估依托泊苷(etoposide,VP-16)、顺铂(cisplatin,DDP)(EP方案)联合重组人血管内皮抑制素对小细胞肺癌(small-cell lung cancer,SCLC)NCI-H446细胞的促凋亡和抑制细胞增殖的协同作用。方法:EP方案、重组人血管内皮抑制素单药以及EP方案联合重组人血管内皮抑制素作用于NCI-H446细胞72h后,采用CCK-8(cell counting kit-8)法测定药物对NCI-H446细胞的增殖抑制作用,FCM检测药物对NCI-H446细胞的细胞周期分布的影响,ELISA法检测药物对NCI-H446细胞分泌血管内皮细胞生长因子(vascular endothelial cell growth factor,VEGF)水平的影响。结果:EP方案联合重组人血管内皮抑制素的细胞增殖抑制率明显高于EP方案组(P<0.01)。EP方案组和EP方案联合重组人血管内皮抑制素组的NCI-H446细胞大多被阻滞于G1期,EP方案联合重组人血管内皮抑制素组的NCI-H446细胞凋亡率显著高于EP方案组(P<0.01)。与EP方案和重组人血管内皮抑制素单药相比,EP方案联合重组人血管内皮抑制素可显著抑制NCI-H446细胞分泌VEGF(P<0.05)。结论:EP方案联合重组人血管内皮抑制素在抑制SCLCNCI-H446细胞增殖和促细胞凋亡方面,具有协同作用。

Objective： To examine the synergistic effect of EP regimen （etoposide plus cisplatin） and recombinant human vascular endostatin （Endostar） on proliferation inhibition and apoptosis of small-cell lung cancer （SCLC） cell line NCI-H446. Methods： NCI-H446 cells were treated with EP regimen, Endostar or EP regimen combined with Endostar for 72 h. The proliferation-inhibitory activity and the change of cell cycle distribution of NCI-H446 cells were detected by cell counting kit-8 （CCK-8） and flow cytometry （FCM）, respectively. The expression of vascular endothelial cell growth factor （VEGF） was detected by ELISA. Results：The inhibitory rate of cell proliferation in EP regimen combined with Endostar group was significantly higher than that in the EP regimen group （P〈0.01）. The NCI-H446 cells were mainly arrested in phase G1 during the cell cycle in the EP regimen group and the EP regimen combined with Endostar group. The apoptotic rate in the EP regimen combined with Endostar group was significantly higher than that in the EP regimen group （P〈0.01）. The expression of VEGF was significantly decreased in the EP regimen combined with Endostar group as compared with those in the EP regimen group and the single Endostar group （P0.05）. Conclusion： There is a significant synergic inhibitory effect of EP regimen combined with Endostar on the proliferation SCLC cell line NCI-H446.